OCTAPHARMA

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1983-01-01

Employees: -

Market Cap: -

Website: https://www.octapharma.com/

Clinical Trials

Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection

Completed

Conditions: Covid19

Interventions: Drug: Antithrombin III

First Posted Date: 2020-12-03

Last Posted Date: 2023-10-10

Lead Sponsor: Octapharma

Target Recruit Count: 300

Registration Number: NCT04651400

Locations: 🇸🇪
ECMO Centre Karolinska, Stockholm, Sweden
🇩🇪
Octapharma Research Site, Essen, Germany

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Phase 3

Recruiting

Conditions: Primary Immune Deficiency

Interventions: Biological: Newnorm

First Posted Date: 2020-11-23

Last Posted Date: 2024-12-05

Lead Sponsor: Octapharma

Target Recruit Count: 50

Registration Number: NCT04640142

Locations: 🇺🇦
Octapharma Research Site, Lviv, Ukraine

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

Phase 3

Completed

Conditions: Pediatric Acute-Onset Neuropsychiatric Syndrome

Interventions: Biological: Panzyga
Other: Placebo

First Posted Date: 2020-08-11

Last Posted Date: 2024-11-05

Lead Sponsor: Octapharma

Target Recruit Count: 71

Registration Number: NCT04508530

Locations: 🇸🇪
Octapharma Research Site, Stockholm, Sweden

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Phase 3

Active, not recruiting

Conditions: Hypogammaglobulinemia
Chronic Lymphocytic Leukemia

Interventions: Biological: Panzyga
Other: Placebo

First Posted Date: 2020-08-06

Last Posted Date: 2024-10-23

Lead Sponsor: Octapharma

Target Recruit Count: 247

Registration Number: NCT04502030

Locations: 🇹🇷
Octapharma Research Site, Melikgazi/Kayseri, Turkey

Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

Phase 3

Completed

Conditions: Covid-19

Interventions: Biological: Octagam 10%
Other: Saline Solution

First Posted Date: 2020-05-22

Last Posted Date: 2024-01-18

Lead Sponsor: Octapharma

Target Recruit Count: 207

Registration Number: NCT04400058

Locations: 🇺🇦
Octapharma Research Site, Kremenchuk, Ukraine

Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data

Completed

Conditions: Bleeding

Interventions: Drug: Fibryga

First Posted Date: 2019-09-27

Last Posted Date: 2021-05-13

Lead Sponsor: Octapharma

Target Recruit Count: 200

Registration Number: NCT04106895

Locations: 🇫🇷
Le Plessis Robinsin Study Site, Le Plessis-Robinson, France
🇫🇷
Nantes Study Site, Nantes, France
🇫🇷
Marseille Study Site, Marseille, France

and more 2 locations

Effectiveness and Tolerability of Eqwilate in Real-life Conditions

Conditions: VWD - Von Willebrand's Disease

Interventions: Biological: Eqwilate

First Posted Date: 2019-09-27

Last Posted Date: 2021-03-05

Lead Sponsor: Octapharma

Target Recruit Count: 47

Registration Number: NCT04106908

Locations: 🇫🇷
Caen Study Site, Caen, France
🇫🇷
Clamart Study Site, Clamart, France
🇫🇷
Rennes Study Site, Rennes, France

and more 6 locations

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Phase 3

Completed

Conditions: Von Willebrand Diseases

Interventions: Drug: Wilate

First Posted Date: 2019-08-12

Last Posted Date: 2023-10-25

Lead Sponsor: Octapharma

Target Recruit Count: 43

Registration Number: NCT04052698

Locations: 🇧🇾
Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus
🇺🇦
State Institution "National Children's Specialized Hospital "OKHMATDYT" of the Ministry of Health of Ukraine," Center of Hemostasis Pathology, Kyiv, Ukraine
🇧🇬
"Specialized Hospital for Active Treatment of Haematological Diseases" EAD, Sofia, Sofia, Bulgaria

and more 11 locations

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Completed

Conditions: Von Willebrand Diseases

Interventions: Drug: Von Willebrand Factor-Containing Product

First Posted Date: 2019-08-12

Last Posted Date: 2023-12-07

Lead Sponsor: Octapharma

Target Recruit Count: 56

Registration Number: NCT04053699

Locations: 🇭🇺
Debreceni Egyetem Klinikai Központ, Regionális Haemophilia és Thrombophilia Központ, Debrecen, Hungary
🇱🇧
American University of Beirut Medical Center, Beirut, Lebanon
🇧🇬
"UMHAT Sveta Marina" EAD., Varna, Bulgaria

and more 12 locations

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Phase 1

Terminated

Conditions: Severe Hemophilia A

Interventions: Drug: OCTA101

First Posted Date: 2019-08-06

Last Posted Date: 2022-04-08

Lead Sponsor: Octapharma

Target Recruit Count: 30

Registration Number: NCT04046848

Locations: 🇧🇬
Specialized Hospital for Active Treatment of Hematological Diseases EAD Clinic of Clinical Hematology, Sofia, Bulgaria

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy